Using a PKR Inhibitor Assay in the Fight Against Viruses
Tuesday, 01 June 2021
Can a novel PKR inhibitor help lead to new treatments for viral infections? – While the human immune response is astounding and works hard to keep us alive in the face of the many germs we encounter daily, it is exceedingly complex. Unlike the adaptive immune response, the innate response acts quickly. It is considered
- Published in Emerging Targets, HTS Assays, Innate Immunity
No Comments
TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments
Monday, 17 May 2021
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
- Published in Company, Emerging Targets
Can DDX3 Inhibitors Lead to the Discovery of Antiviral Therapies?
Tuesday, 04 May 2021
DDX3 inhibitors could unlock new treatments for viral diseases. The human immune response is extraordinary and incredibly complex. As the first line of defense against pathogens and foreign DNA, the innate response acts quickly. Viruses activate innate immunity as the host has proteins that recognize viral components. The innate immune response relies on several cell
- Published in Emerging Targets, HTS Assays
NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases
Tuesday, 20 April 2021
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
A Kinase Assay Kit to Interrogate Innate Immunity Targets
Thursday, 15 April 2021
Kinases are essential players in cellular functions such as cell signaling, cellular transport, and protein regulation. For these reasons, many kinases are innate immunity targets. A kinase assay kit is ideal whether used for drug screening and dose-response measurements or detection when studying a particular cellular pathway. A universal ADP assay allows researchers to screen
- Published in HTS Assays, Products
Small GTPase Modulation: GDP Assays to Accelerate Discovery
Wednesday, 24 March 2021
Cancer is complex, which makes determining the culprit as well as individual treatment extremely challenging. A variety of cancer types exist with a multitude of contributors. As the second leading cause of death in the US, cancer has been a target scientists have been battling for decades. When DNA is damaged or mutations occur, cells
- Published in HTS Assays, Products
BellBrook Labs Receives NIH Funding for Novel Approach to Stimulating Antitumor Immunity
Tuesday, 09 March 2021
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small
Accelerating Discovery of Kinase Inhibitors Using an ADP Assay
Tuesday, 23 February 2021
An ADP assay can be used to study the activity of enzymes that phosphorylate substrates leading to signaling events in the body. One of a variety of post-translational modifications, protein phosphorylation regulates a diverse group of cellular functions. In cancer, abnormal phosphorylation events often play a role in proliferation, survival, motility, metabolism, and angiogenesis.1 PI3K
- Published in HTS Assays
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Thursday, 11 February 2021
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
- Published in Emerging Targets, HTS Assays, News
Using a Universal GMP Assay for PDE Research
Thursday, 28 January 2021
A universal GMP assay to aid in PDE research and potential COVID-19 disruption. – Phosphodiesterase enzymes (PDEs) modulate pathways throughout the body. Since unregulated PDEs contribute to disease in many cases, it makes sense therapies that inhibit these enzymes have the potential to treat several different ailments. These include cardiovascular and respiratory issues, diabetes, fibrotic
- Published in HTS Assays, Uncategorized